Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Rubicon reported Q3 financial results that beat our estimates.</li>
<li>Revenue came in at $15.6M (+16% YoY) compared to our estimate of $15.1M and adjusted EBITDA came in at $1.7M (11% margin) compared to our estimate of $1.0M.</li>
<li>ROMJ also announced that Glen Ibbott has been appointed as CFO, its newly acquired Cascadia facility has received its Health Canada license, and that it has entered into a new credit agreement for $4.0M.</li>
</ul>


Rubicon reported Q3 financial results that beat our estimates.
Revenue came in at $15.6M (+16% YoY) compared to our estimate of $15.1M and adjusted EBITDA came in at $1.7M (11% margin) compared to our estimate of $1.0M.
ROMJ also announced that Glen Ibbott has been appointed as CFO, its newly acquired Cascadia facility has received its Health Canada license, and that it has entered into a new credit agreement for $4.0M.


ROMJ: Strong Growth in Q3; Various Catalysts Ahead

Rubicon Organics

ROMJ: Strong Growth in Q3; Various Catalysts Ahead